Clinical Trial Update: Study of Evobrutinib in Participants With RMS (evolutionRMS 1) [Phase 3]

View source ↗

Summary

A Phase 3 study of evobrutinib in relapsing multiple sclerosis was terminated, with results posted on ClinicalTrials.gov.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Evobrutinib (evobrutinib)

Snippet

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2025-06-12